Facebook Linkedin Tumblr Twitter
Home Blog Page 14

Cannabis Sector Weekly Roundup

By
ME Staff
-
  • BioHarvest Sciences Inc., Icanic Brands Co Inc. & Cann Group Ltd.  Among Top Cannabis Gainers For The Week.
  • TerrAscend Corp & Columbia Care Inc Made the Headlines with Positive News.
  • Key Developments to Note in the Proceedings of the Federal Legalization of Marijuana

With State cannabis legalization ramping up across the U.S. and chances of Federal Legalization improving, here is a breakdown of the top cannabis movers for the week and an outline of the essential news and reporting that developed throughout the week.

Top Cannabis Gainers For This Week & Top Cannabis Stocks to Keep a Close Eye On

 

#1: Icanic Brands Co Inc (CNSX: ICANF)

 

Icanic Brands Co Inc. (ICANF) (ICAN.CN) is a wellness company focused on the development, manufacturing, marketing, and distribution of botanically-based consumable products. They offer an optimal oral spray delivery system under the brand name GanjaGold and Taylor’s. The Company has one reportable business segment being the cannabis sector. Geographically, it derives a majority of revenue from the United States.

 

This week, Icanic Brands was one of the top gainers in the cannabis sector. The shares of Icanic Brands closed up 11.32% at $0.26, with an estimated market cap of $59.3M. The catalyst for this high percentage gain was the announcement of a Proposed Acquisition by Icanic Brands. They announced that the Company had signed a binding letter of intent to acquire LEEF Holdings, Inc. This was an excellent follow-up to the Record Financial Results that Icanic Brands announced from the last quarterly report.

 

#2: Bioharvest Sciences Inc (CNSX: BHSC)

 

BioHarvest Sciences Inc. (CNVCF) (BHSC.CN) is a developer and owner of proprietary and patent-protected bio-farming technology. Its industrial large-scale plant cell growth technology can directly and constantly produce the active plant ingredients without the necessity to grow the plant itself. BioHarvest has already validated this technology through the production of VINIA™, a red grape cells functional food/dietary supplement produced and sold by BioHarvest. By adopting this technology to the Cannabis plant and building adequate cells production capacity, the Company’s objective is to be the supplier of Cannabis for both medicinal and recreational legal use.

 

BioHarvest was also another top gainer in the cannabis sector this week. The shares of BioHarvest closed up 7.64% at $0.32. BioHarvest’s market cap is at an estimate of $138.0M. BioHarvest high percentage gain was triggered by BioHarvest announcement that it had successfully scaled its Cannabis cells with trichomes production by a factor of 250x. BioHarvest also stated that they are now growing Cannabis in medium-scale bioreactors, paving the way for their next scale-up milestone, where they will reach industrial-scale production

 

#3: Cann Group Ltd (ASX: CAN)

Cann Group Limited (CNGGF) engages in the cultivation of medicinal Cannabis for medicinal and research purposes. Cann’s vision is to be a leading developer and supplier of Cannabis, cannabis resin, and medicinal cannabis products.

Cann was also another top gainer in the cannabis sector this week. Its shares closed up 9.2% at $0.24. Cann has an estimated market cap of $73.5M.

 

#4: TerrAscend Corp (CSE: TER:CNX)( OTCQX: TRSSF)

TerrAscend Corp. (TRSSF) (TER.CN) is a leading North American cannabis operator. It carries out licensed marijuana cultivation and processing operations in Maryland and has licensed marijuana production in Canada.

Recently TerrAscend has been making the headlines severally, and this week they were at it again. This week they announced the East Coast launch of its premium edible brand Valhalla Confections. Valhalla’s soft lozenges gained popularity on the West Coast as one of the most prevalent cannabinoids; therefore, this launch of Valhalla in the East Coast can be an excellent move by TerrAscend; subsequently, this stock must be watched with a keen eye.

 

#5: Columbia Care Inc. (OTCMKTS: CCHWF)

 

Columbia Care Inc. (CCHWF) (CCHW.CN) is one of the largest and most experienced cultivators, manufacturers, and providers of cannabis products in the U.S.

 

This week the Company announced that it had received approval from the Florida Department of Health’s Office of Medical Marijuana Use (OMMU) to operate as Cannabist. They aim to rebrand their Florida dispensaries as Cannabist. We all know that ‘approvals’ can be a massive catalyst for a Stock to spike; approvals can bring liquidity and volatility to the stock. This is why we feel that Columbia Care is an excellent stock to put on any trader’s watch list.

 

 #6: Cresco Labs Inc. (OTCMKTS: CRLBF)

 

Cresco Labs Inc. (CRLBF) (CL.CN) is another company that should be on any smart Trader radar. Cresco Labs is one of the largest multi-state, vertically integrated cannabis companies. They control the cultivation, manufacturing, extraction, and packaging of their cannabis products.

 

Cresco Labs stock is up 58.27% over the last 12 months, and on Thursday, Sep 2, Cresco had a huge spike; this is because the Company closed its $90 million acquisition of Cultivate in Massachusetts. This is a massive deal for Cresco Labs, and this is why you should closely watch out for Cresco in the coming few days.

 

Key Developments in the Federal Legalization of Marijuana

 

Democratic Governor of California Gavin Newsom signed a bill that will exclude and exempt states regulations on Cannabis produced under a research production permit (DEA). In addition, the state’s top cannabis regulator said that they are working on uniting rulemaking and oversight.

 

Another critical development in the cannabis sector this week was the rally and support for the Sector by a few significant industries and organizations, who are advocates and stakeholders in the cannabis sector. They showed their support to the Sector by submitting comments to the Senate on The Democratic Senate Majority Leader Chuck Schumer’s government draft bill, which aims to legalize marijuana.

 

The National Cannabis Industry Association (NCIA) was one of the organizations which commented on Schumer’s bill of federal legalization of marijuana.  In their statement, they said, “Given our demonstrated focus on engaging with the people most directly impacted by cannabis policy reform, we hope the breadth and depth of our feedback will enable you to enact sound legislation which fosters the growth of a thriving and equitable legal cannabis industry.” The organization also added on their remarks by stating that “NCIA is committed to creating a vibrant legal industry that can sustain thousands of well-paying jobs while responsibly serving adult consumers and medical patients who rely on cannabis for relief.”

 

In another report, The Marijuana Policy Project (MPP) said in its letter that even if federal legalization is a necessity, the rollout should be carried out thoughtfully and gradually. This will, in turn, avoid jeopardizing efforts to promote equity in the industry throughout the various states in The United States of America. In the Statement, MPP said that “While we are enthusiastic about the goals of the CAO Act Discussion Draft, we believe the regulatory aspects need significant clarification and revision to avoid unintended consequences,” In addition to this, MPP states policies director, Karen O’Keefe, wrote. “Our two major areas of concern are the possible upending of state licensing and regulatory systems—driving sales underground—and the impact on medical cannabis access, including for those under the age of 21.”

 

Elsewhere, Republican Thomas Massie, who is the Representative for Kentucky’s 4th congressional district, tweeted, “I will defend your right to ingest, consume, or receive any vaccine, food, drug, or treatment you want, whether the government approves it or not… I don’t care if you take mushrooms or marijuana.”

Story continues below

ICONIX BRAND GROUP, INC. (NASDAQ:ICON) Files An 8-K Other Events

By
ME Staff 8-k
-

ICONIX BRAND GROUP, INC. (NASDAQ:ICON) Files An 8-K Other Events
Item 8.01.

On June 28, 2021, Red Diamond Holdings S.à r.l, an indirect wholly-owned subsidiary of Iconix Brand Group, Inc. (the “Company”), entered into an IP assignment agreement (the “Agreement”) to sell certain intellectual property rights in the Republic of India relating to the Lee Cooper® brand to Iconix Life>
In order to fund the Consideration, the Company contributed towards a rights issue in Iconix India and the Company anticipates using the net proceeds to repay amounts due under its existing financing arrangements, and otherwise for general corporate purposes.

Forward-Looking Statements
This Form 8-K contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The matters discussed in this Form 8-K involve estimates, projections, goals, forecasts, assumptions, risks and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. All statements in this Form 8-K that are not purely historical facts are forward-looking statements, including statements containing the words “may,” “will,” “expect,” “anticipate,” “intend,” “estimate,” “continue,” “believe,” “plan,” “project,” “will be,” “will continue,” “will likely result” or similar expressions. Any forward-looking statement inherently involves risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. The Company discusses certain of these factors more fully in its additional filings with the Securities and Exchange Commission (the “SEC”), including its annual report on Form 10-K for the fiscal year ended December 31, 2020 and a subsequent quarterly report on Form 10-Q filed with the SEC, and this Form 8-K should be read in conjunction with those reports, together with all of the Company’s other filings, including other current reports on Form 8-K, through the date of this Form 8-K. The Company urges you to consider all of these risks, uncertainties and other factors carefully in evaluating the forward-looking statements contained in this Form 8-K.
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Since the Company operates in a rapidly changing environment, new risk factors can arise and it is not possible for the Company’s management to predict all such risk factors, nor can the Company’s management assess the impact of all such risk factors on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. The Company’s future results, performance or achievements could differ materially from those expressed or implied in these forward-looking statements. The Company does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances occurring after the date hereof or to reflect the occurrence of unanticipated events, except as may be required by law.
About ICONIX BRAND GROUP, INC. (NASDAQ:ICON)

Iconix Brand Group, Inc. is a brand management company. The Company owns a diversified portfolio of consumer brands across women’s, men’s, home and entertainment categories. The Company operates through five segments: men’s, women’s, home, entertainment and corporate. The Company’s brand portfolio includes brands, such as Candie’s, Bongo, Joe Boxer, Rampage, Mudd, London Fog, Mossimo, Ocean Pacific/OP, Danskin/Danskin Now, Rocawear/Roc Nation, Cannon, Royal Velvet, Fieldcrest, Charisma, Starter, Waverly, Ecko Unltd/Mark Ecko Cut & Sew, Zoo York, Umbro, Lee Cooper, Strawberry Shortcake and Artful Dodger, and interests in Material Girl, Peanuts, Ed Hardy, Truth or Dare, Modern Amusement, Buffalo, Nick Graham Hydraulic and PONY brands. It operates in various geographic regions, including the United States, Japan and Other (which principally represent Latin America and Europe).

Story continues below

Compass, Inc. (TSE:CMZ.UN) Files An 8-K Material Modification to Rights of Security Holders

By
ME Staff 8-k
-

Compass, Inc. (TSE:CMZ.UN) Files An 8-K Material Modification to Rights of Security Holders
Item 3.03.


About Compass, Inc. (TSE:CMZ.UN)

COMPASS Income Fund is a Canada-based closed-end investment trust. The investment objective of the Fund is to provide unitholders with a stable stream of monthly distributions. The Fund invests in a diversified portfolio comprised primarily of high yielding equity securities of issuers operating in various industries and geographic regions. It has investments in various sectors, such as real estate, energy, financials, pipelines, industrials, consumer discretionary, utilities, cash and short-term investments, and other assets. The Fund’s financial instruments may include fixed income, equities, structured products, derivatives, cash, accounts receivable-portfolio securities sold, accounts payable-portfolio securities purchased, accounts payable and accrued liabilities, redemptions payable and distributions payable. Middlefield Limited is the trustee and manager of the Fund. The co-advisors of the Fund are Middlefield Capital Corporation and Guardian Capital LP.

Story continues below

Hudson Technologies, Inc. (NASDAQ:HDSN) Files An 8-K Other Events

By
ME Staff 8-k
-

Hudson Technologies, Inc. (NASDAQ:HDSN) Files An 8-K Other Events
Item 8.01

On June 29, 2021, Hudson Technologies, Inc. (the “Company”) issued a press release, attached hereto as Exhibit 99.1, announcing that the United States Defense Logistics Agency exercised its option to extend, for an additional five years to July 2026, the term of the Company’s existing five-year contract for sales to the Department of Defense.

(d) Exhibits

Exhibit 99.1 Press Release issued June 29, 2021.

 


HUDSON TECHNOLOGIES INC /NY Exhibit
SEC.gov | Request Rate Threshold Exceeded html {height: 100%} body {height: 100%; margin:0; padding:0;} #header {background-color:#003968; color:#fff; padding:15px 20px 10px 20px;font-family:Arial,…
To view the full exhibit click here

About Hudson Technologies, Inc. (NASDAQ:HDSN)

Hudson Technologies, Inc. is a refrigerant services company. The Company provides solutions to recurring problems within the refrigeration industry. Its products and services include refrigerant and industrial gas sales; refrigerant management services, which consist of reclamation of refrigerants, and RefrigerantSide services, which consist of system decontamination. Its refrigerant and industrial gas sales include selling of reclaimed and virgin (new) refrigerants to various customers in a range of segments of the air conditioning and refrigeration industry. It provides refrigerant management services, which also include laboratory testing through its laboratory, and banking services. It provides decontamination and recovery services that are performed at a customer’s site using its Zugibeast system under its RefrigerantSide services. The Company also participates in the generation of carbon offset projects as a component of its products and services.

Story continues below

3D PIONEER SYSTEMS, INC. (OTCMKTS:DPSM) Files An 8-K Entry into a Material Definitive Agreement

By
ME Staff 8-k
-

3D PIONEER SYSTEMS, INC. (OTCMKTS:DPSM) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01

(d) Exhibits

Exhibit No. Description
10.1 Share Sale Agreement
99.1 Press Release issued June 24, 2021


3D PIONEER SYSTEMS, INC. Exhibit
EX-10.1 2 ex10-1.htm   EXHIBIT 10.1   Share Sale Agreement   BETWEEN   3D Pioneer Systems Inc.   AND Host Group of Companies Pty Ltd ACN 085 418 159   AND   Vantis Partners Pty Ltd ACN 142 953 731         This Acquisition Agreement (“Agreement”) is entered into this June of 23,…
To view the full exhibit click here

About 3D PIONEER SYSTEMS, INC. (OTCMKTS:DPSM)

3D Pioneer Systems, Inc. is engaged in implementing of three-dimensional (3D) printing in the gaming and entertainment industries. The Company provides 3D printing hardware, software and accessories. The Company’s Wyatt is a 3D printer with features, such as wireless connectivity, Web interface and remote mobile access, and control. The Company’s Appaloza is an online marketplace and platform for designing, collaborating and printing. The Company’s Appaloza is a 3D marketplace where both designs can be sold, shared, modified and printed. The Company’s Appaloza enables direct communication and control with fused deposition modeling (FDM) 3D printers on the market. The Company’s also offers The Whip, a Web enabled 3D printer controller. The Company is also engaged in developing a portfolio of mobile games playable on all platforms, including Internetwork Operating System (iOS), Android, Windows and Linux. The Company operates offices in the United States and the United Kingdom.

Story continues below

TECHPRECISION CORPORATION (OTCMKTS:TPCS) Files An 8-K Entry into a Material Definitive Agreement

By
ME Staff 8-k
-

TECHPRECISION CORPORATION (OTCMKTS:TPCS) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01


TECHPRECISION CORP Exhibit
EX-10.1 2 tm2120896d1_ex10-1.htm EXHIBIT 10.1     Exhibit 10.1     AMENDMENT TO AMENDED AND RESTATED LOAN PURCHASE AND SALE AGREEMENT   THIS AMENDMENT TO AMENDED AND RESTATED LOAN PURCHASE AND SALE AGREEMENT (the “Amendment”),…
To view the full exhibit click here

About TECHPRECISION CORPORATION (OTCMKTS:TPCS)

TechPrecision Corporation is a manufacturer of fabricated and machined metal components and systems. The Company offers a range of services required to transform metallic raw materials into precision finished products. It sells finished products to its customers in three industry groups: defense, energy and precision industrial. Its primary business includes the business of its subsidiary, Ranor, Inc. Its operations in China are conducted through its subsidiary, Wuxi Critical Mechanical Components Co., Ltd. (WCMC). WCMC, through its subcontractors, provides precision component fabrication and machining solutions. Its manufacturing solutions include fabrication operations (cutting, press and roll forming, assembly, welding, heat treating, blasting and painting), and machining operations, including computer numerical controlled horizontal and vertical milling centers. Its projects include the manufacturing of products from various traditional, as well as specialty metal alloys.

Story continues below

DELCATH SYSTEMS, INC. (NASDAQ:DCTH) Files An 8-K Unregistered Sales of Equity Securities

By
ME Staff 8-k
-

DELCATH SYSTEMS, INC. (NASDAQ:DCTH) Files An 8-K Unregistered Sales of Equity Securities
Item 3.02 Unregistered Sales of Equity Securities.

As of June 28, 2021, the outstanding shares of common stock, $0.01 par value per share (the “Common Stock”) of Delcath Systems, Inc. (the “Company”) had increased by more than 5% since the last reported shares of Common Stock outstanding.

As of June 28, 2021, the Company had 7,349,777 shares of Common Stock issued and outstanding. The increase in outstanding shares of Common Stock is due to (i) the conversion of 7,651.35 shares of Series E Convertible Preferred Stock into 765,135 shares of Common Stock, (ii) the conversion of 1,122.44 shares of Series E-1 Convertible Preferred Stock into 112,244 shares of Common Stock (iii) the exercise of 3,750 Series F warrants to purchase 3,750 shares of Common Stock, (iv) the exercise of 4,341 Series E and E-1 warrants to purchase 4,341 shares of Common Stock and (v) the exercise of 215,000 pre-funded warrants to purchase 215,000 shares of Common Stock.

About DELCATH SYSTEMS, INC. (NASDAQ:DCTH)

Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company’s system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company’s focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.

Story continues below

DIFFUSION PHARMACEUTICALS INC. (NASDAQ:DFFN) Files An 8-K Submission of Matters to a Vote of Security Holders

By
ME Staff 8-k
-

DIFFUSION PHARMACEUTICALS INC. (NASDAQ:DFFN) Files An 8-K Submission of Matters to a Vote of Security Holders

About DIFFUSION PHARMACEUTICALS INC. (NASDAQ:DFFN)

Diffusion Pharmaceuticals Inc., formerly RestorGenex Corporation, is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The Company’s lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC) is used in various cancer types, in which tumor oxygen deprivation (hypoxia) is known to diminish the effectiveness of treatments. The Company’s Diffusion’s technology is targeted at overcoming treatment-resistance in solid cancerous tumors by combining its lead product candidate, TSC, with standard-of-care radiation and chemotherapy regimens, thus effecting a better patient survival outcome without the addition of harmful side effects. Its clinical development plan targets TSC at the radiation and chemotherapy sensitization of hypoxic tumor types, with an initial focus on primary brain cancer (glioblastoma or GBM), pancreatic cancer, and brain metastases.

Story continues below

EVOKE PHARMA, INC. (NASDAQ:EVOK) Files An 8-K Other Events

By
ME Staff 8-k
-

EVOKE PHARMA, INC. (NASDAQ:EVOK) Files An 8-K Other Events
Item 8.01.  Other Events.

On June 29, 2021, Evoke Pharma, Inc. (“Evoke” or the “Company”), EVERSANA, the Company’s commercialization partner, and The International Foundation for Gastrointestinal Disorders (“IFFGD”), announced Evoke’s membership into IFFGD Industry Council. Evoke will join a likeminded group of organizations and brands focused on bettering patients affected by gastrointestinal disorders. As part of the Industry Council, Evoke will participate in biannual council meetings to gain industry insights and provide feedback on future plans for IFFGD.

In addition to the Industry Council, Evoke is excited to sponsor the IFFDG’s upcoming 30th Anniversary Digestive Health Virtual Walk in August 2021 during Gastroparesis Awareness Month. This walk is a unique fitness event which will provide participants with an opportunity to engage at their own pace and as their health and schedules permit. To honor the thirty years of the IFFGD’s existence, the overall campaign goal is for all participants to collectively walk 10,950 miles over two weeks. Goals will also go beyond physical fitness by encouraging participants to participate in activities that promote general wellness such as scheduling a doctor’s appointment, trying a new gut friendly recipe or starting a log of their meals and/or symptoms.

Safe Harbor Statement

The Company cautions you that statements included in this report that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on the Company’s current beliefs and expectations. These forward-looking statements include statements regarding the Company’s plans to increase awareness of gastrointestinal disorders. The inclusion of forward-looking statements should not be regarded as a representation by the Company that any of its plans will be achieved. Actual results may differ from those set forth in this report due to the risks and uncertainties inherent in the Company’s business, including those described in the Company’s periodic filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to revise or update this report to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

About EVOKE PHARMA, INC. (NASDAQ:EVOK)

Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic delivery of metoclopramide through intranasal administration. The Company has evaluated EVK-001 in a multicenter, randomized, double-blind, placebo-controlled parallel group, dose-ranging Phase IIb clinical trial. The Company has commenced a Phase III clinical trial of EVK-001 in female patients with symptoms associated with acute and recurrent diabetic gastroparesis. The Phase III clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy, safety and population pharmacokinetics of EVK-001 in adult females.

Story continues below

USA EQUITIES CORP. (OTCMKTS:USAQ) Files An 8-K Regulation FD Disclosure

By
ME Staff 8-k
-

USA EQUITIES CORP. (OTCMKTS:USAQ) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

On June 29, 2021, USA Equities Corp. (the “Company”) issued a press release entitled “USA Equities Corp Announces the signing of a Distribution Agreement with a Prominent Physician Management Services Firm For its AllergiEnd® Products and Services.”

A copy of the above-mentioned press release is attached herewith as Exhibit 99.1.

By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD. The Company uses, and will continue to use, its website (https://usaqcorp.com), press releases, and various social media channels, including its Twitter account (https://twitter.com/USAQcorp), its LinkedIn account (https://www.linkedin.com/company/usaqcorp) its Facebook account (https://www.facebook.com/USA-Equities-100113722270622), and its Instagram account (https://www.instagram.com/usaqcorp/) as additional means of disclosing public information to investors, the media and others interested in the Company. It is possible that certain information that the Company posts on its website, disseminated in press releases and on social media could be deemed to be material information, and the Company encourages investors, the media and others interested in the Company to review the business and financial information that the Company posts on its website, disseminates in press releases and on the social media channels identified above, as such information could be deemed to be material information.

ITEM 9.01 Financial Statements and Exhibits

99.1 Press release dated June 29, 2021 entitled “USA Equities Corp Announces the signing of a Distribution Agreement with a Prominent Physician Management Services Firm For its AllergiEnd® Products and Services.”


USA EQUITIES CORP. Exhibit
EX-99.1 2 ex99-1.htm   EXHIBIT 99.1     USA Equities Corp Announces the Signing of a Distribution Agreement with a Prominent Physician Management Services Firm For its AllergiEnd® Products and Services   -Continued Momentum Expanding Independent Care Practitioner Network-   West Palm Beach,…
To view the full exhibit click here

About USA EQUITIES CORP. (OTCMKTS:USAQ)

USA Equities Corp., formerly American Biogenetic Sciences, Inc., is a shell company. The Company focuses to seek new business opportunities, including seeking an acquisition or merger with an operating company. The Company’s subsidiary, USA Equities Trust, Inc., is engaged in acquiring real estate. The Company was engaged in the research, development and marketing of cardiovascular and neurobiology products for the purpose of commercial development and vaccines distribution. The Company’s products were designed for in vitro and in vivo diagnostic procedures and therapeutic drugs, and its products had been identified for use in the treatment of epilepsy, migraine and mania, neurodegenerative diseases, coronary artery diseases and cancer. The Company has no operations.

Story continues below
1...131415...14,629Page 14 of 14,629

EDITOR PICKS

POPULAR POSTS

POPULAR CATEGORY

© Market Exclusive 2019